Idiopathic Pulmonary Fibrosis: Real World Application of Diagnostic and Therapeutic Advances

The recognition and diagnosis of idiopathic pulmonary fibrosis (IPF) is a clinical challenge requiring a high index of suspicion, as well as great sensitivity to possible signs and symptoms of this uncommon disease. In this activity, 2 community-based pulmonologists present the case of a patient with suspected IPF, and discuss the challenges of diagnosing and treating a patient who presents with mild exertional dyspnea. Activity Chair, Harold R. Collard, MD, provides his insights on this real-world patient scenario, highlighting opportunities and specific strategies to improve the diagnosis and treatment of IPF.


Harold R. Collard, MD

Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Director, Interstitial Lung Disease Program
University of California, San Francisco




Hassan Bencheqroun, MD, FCCP
Pacific Pulmonary Medical Group
Assistant Clinical Professor, Interventional Pulmonary and Clinical Care
University of California, Riverside School of Medicine
Riverside, California

Ahmed S. El-Bershawi, MD
Medical Director and CEO
Pacific Pulmonary Medical Group
Medical Director, ICU & Respiratory Departments
Riverside Community and Parkview Community Hospitals
Riverside, California

Target audience

Pulmonologists and other clinicians involved in the diagnosis and management of idiopathic pulmonary fibrosis.


Complete these 6 easy steps to participate in this activity:

  1. Complete the pre-activity Clinical Impact Challenge quiz, which will allow you to compare your answers at the beginning of the activity to your post-activity answers. 
  2. Listen to the introduction by Dr. Collard.
  3. Read the case presentation.
  4. Listen to the community-based physicians' discussion about the case.
  5. Listen to Dr. Collard’s conclusions on the case and final remarks on IPF diagnosis and treatment.
  6. Complete the post-activity quiz and evaluation form to claim your credit.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Supported by an educational grant from Genentech.


Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Attendance
Course opens: 
Course expires: 

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Attendance


Please login or register to take this course.